ITP and the Center of QuantumBioSciences is part of newly approved Collaborative Research Center 1279

ITP and the Center of QuantumBioSciences is part of newly approved Collaborative Research Center 1279 on “Exploiting the Human Peptidome for Novel Antimicrobial and Anticancer Agents”. Our team contributes to the CRC with a project on hyperpolarized nanodiamond as contrast agents for cancer research. Funded initially for a period of 4 years the CRC may be extended for a duration of up to 12 years.

https://www.uni-ulm.de/med/fakultaet/med-detailseiten/news-detail/article/rund-121-millionen-neuer-peptid-sonderforschungsbereich-koerpereigene-wirkstoffe-gegen-hiv/